Dimerix (DXB) H1 2026 earnings summary

Executive summary

• Reported a net loss of $15.97 million for the half-year ended 31 December 2025, compared to a $12.91 million loss in the prior year period.

• Achieved full target recruitment (>286 patients) for the ACTION3 Phase 3 clinical trial of DMX-200 in FSGS, with orphan drug designation received in Japan, US, Europe, and UK.

• License income increased to $2.12 million from $0.29 million year-over-year, reflecting progress in commercial partnerships.

• Ended the period with $38.5 million in cash and cash equivalents.

Financial highlights

• Research and development expenses rose to $21.25 million from $11.37 million year-over-year, mainly due to the ongoing Phase 3 study.

• Corporate and administration expenses increased to $1.94 million from $1.41 million year-over-year.

• License income recognized was $2.12 million, up from $0.29 million in the prior period.

• Net cash outflow from operations was $29.86 million, compared to $2.25 million in the prior year.

• Basic and diluted loss per share was 2.66 cents, compared to 2.33 cents in the prior year.

Outlook and guidance

• Directors remain confident in the ability to execute operational plans and access required funding, supported by global commercial partnerships and licensing agreements.

• The company’s strategy is underpinned by advancing clinical programs and securing licensing arrangements in key territories.